UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
Recruiting · NCT03503331 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Alabama at Birmingham
View the official record on ClinicalTrials.gov →Interventions studied
[C-11]PiB-PET/MRI
What this trial is about
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
Who can take part
Age range
50 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- \- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).
- \. Negative urine or serum B-hCG test within 2 days of \[C-11\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
Exclusion criteria
- Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).
- Inability or contraindication for undergoing MRI and/or PET imaging
- Inability to participate in the imaging studies due to severity of dementia
Where it is running
1 location listed across 1 US state.
- University of Alabama at Birmingham Medical Center - Birmingham, Alabama, United States